CMS has contracted with FMQAI to develop and maintain medication-related quality measures. A set of seven
new medication measures has been developed using Medicare administrative claims data. These measures are
based on the Institute of Medicine domains of safety and effectiveness and specifically focus on improving
medication adherence, appropriateness of therapy, and patient outcomes. The medication measures were
developed for state and/or plan-level measurement, but are currently under evaluation for use in other
settings of care (i.e. physician offices).
The proposed measures are:
Process Measures I: Adherence Measures
• Adherence to Antipsychotics for Individuals with Schizophrenia
• Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder
• Adherence to Antiplatelet Treatment after Stent Implantation
Process Measures II: Appropriate Therapy Measures
•Polytherapy with Oral Antipsychotics
•Avoiding Acetaminophen Toxicity
•Short-Acting Opioid Formulation for Breakthrough Pain in Individuals with Cancer
•Bleeding Outcomes Related to Oral Anticoagulants
These measures address many clinical issues, including psychiatry/behavioral health, cardiovascular/ischemic
heart disease, cancer/pain management, and patient safety. CMS and FMQAI appreciate the time and effort
healthcare professionals and organizations invest in providing comments.
The public comment period will be open until 11:59 pm ET on Wed May 11, 2011. All feedback submitted within
the public comment period will be reviewed and considered. To submit comments on the above-mentioned
medication measures and to view the Measure Information Forms, please visit
. A summary of all comments received will be
posted approximately four weeks after the public comment period closes Click here to see.